Monoamine Oxidase Inhibitors

P. M. Wax

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Monoamine oxidase inhibitors (MAOIs) were the first antidepressants marketed in the beginning of the 1950s. They were found to be associated with serious drug "drug and drug" food adverse reactions manifested by symptoms of serious hyperadrenergic and hyperserotenergic excess. They have not been used as first-line antidepressants for many years, although they are still occasionally used to treat atypical and refractory depression. Selegiline, a selective monoamine oxidase B inhibitor, is used in the treatment of Parkinson's disease and is less likely to cause similar adverse reactions.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Toxicology
Subtitle of host publicationThird Edition
PublisherElsevier
Pages389-390
Number of pages2
ISBN (Electronic)9780123864543
ISBN (Print)9780123864550
DOIs
StatePublished - Jan 1 2014

Keywords

  • Isocarboxazid
  • Moclobemide
  • Monomamine oxidase inhibitor
  • Phenelzine
  • Selegiline
  • Serotonin syndrome
  • Tranylcypromine
  • Tryamine

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Monoamine Oxidase Inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Wax, P. M. (2014). Monoamine Oxidase Inhibitors. In Encyclopedia of Toxicology: Third Edition (pp. 389-390). Elsevier. https://doi.org/10.1016/B978-0-12-386454-3.00753-3